High-dose cytosine arabinoside in the treatment of acute myeloid leukaemia
- 1 March 1997
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 11 (1) , 39-45
- https://doi.org/10.1016/s0268-960x(97)90005-9
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]Blood, 1996
- 5 Treatment and prognostic factors in acute myeloid leukaemiaBailliere's Clinical Haematology, 1996
- Post-Remission Treatment of Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.Journal of Clinical Oncology, 1993
- Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemiaBlood, 1992
- Varying intensity of postremission therapy in acute myeloid leukemiaBlood, 1992
- High-dose cytosine arabinoside intensification for acute nonlymphocytic leukemia in patients over 56 years of ageAnnals of Hematology, 1992
- High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adultsBlood, 1991
- Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemiaAnnals of Hematology, 1986